Immunogenicity and Safety of the 13-valent Pneumococcal Conjugate Vaccine in Patients with Immunocompromising Conditions: a Review of Available Evidence

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2020 Jun 13

PMID 32530360

Citations 6

Authors

Erica Chilson

Daniel A Scott

Beate Schmoele-Thoma

Wendy Watson

Mary M Moran

Raul Isturiz

Affiliations

Soon will be listed here.

Abstract

Immunocompromising conditions increase the risk of invasive pneumococcal disease (IPD). Vaccine uptake in patients with these conditions may be low in part because of concerns about decreased immunogenicity and safety in these high-risk groups. We conducted a literature search to identify publications describing antibody responses to 13-valent pneumococcal conjugate vaccine (PCV13) in immunocompromised individuals recommended for PCV13 vaccination by the US Advisory Committee on Immunization Practices (ACIP). This review summarizes immunogenicity data from 30 publications regarding the use of PCV13 comprising 2406 individuals considered at high risk for IPD by the ACIP. Although antibody responses to PCV13 in individuals with immunocompromising and high-risk conditions were variable and generally lower compared with healthy controls, the vaccine was immunogenic and was largely well tolerated. Based on these findings, concerns regarding immunogenicity and safety of PCV13 are not supported and should not be barriers to vaccination in high-risk populations.

Citing Articles

Analysis of Adverse Events Post-13-Valent Pneumococcal Vaccination among Children in Hangzhou, China.

Wang J, Du J, Liu Y, Che X, Xu Y, Han J Vaccines (Basel). 2024; 12(6).

PMID: 38932305 PMC: 11209216. DOI: 10.3390/vaccines12060576.

Dutch Healthcare Professionals' Opinion on the Allocation of Responsibilities concerning Prescribing and Administering Medically Indicated Vaccines to Immunocompromised Patients.

Te Linde E, Doornekamp L, Daenen K, van Gorp E, Bruns A Vaccines (Basel). 2023; 11(3).

PMID: 36992271 PMC: 10058813. DOI: 10.3390/vaccines11030686.

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China.

Hu Y, Pan X, Chen F, Wang Y, Liang H, Shen L Hum Vaccin Immunother. 2022; 18(1):2035141.

PMID: 35240930 PMC: 9009923. DOI: 10.1080/21645515.2022.2035141.

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.

Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X Clin Infect Dis. 2021; 75(3):390-398.

PMID: 34940806 PMC: 9427137. DOI: 10.1093/cid/ciab990.

Reducing Delays in Diagnosing Primary Immunodeficiency Through the Development and Implementation of a Clinical Decision Support Tool: Protocol for a Quality Improvement Project.

Kumar B, Zetumer S, Swee M, Endelman E, Suneja M, Davis B JMIR Res Protoc. 2021; 11(1):e32635.

PMID: 34587114 PMC: 8767470. DOI: 10.2196/32635.

References

Ariza-Heredia E, Gulbis A, Stolar K, Kebriaei P, Shah D, McConn K . Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice. Transpl Infect Dis. 2014; 16(6):878-86. DOI: 10.1111/tid.12312. View

Locke F, Menges M, Nishihori T, Nwoga C, Alsina M, Anasetti C . Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. Bone Marrow Transplant. 2015; 51(2):291-4. PMC: 5726387. DOI: 10.1038/bmt.2015.239. View

Rossheim A, Young A, Siik J, Cunningham T, Troy S . Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults. Hum Vaccin Immunother. 2016; 12(8):2117-2123. PMC: 4994738. DOI: 10.1080/21645515.2016.1160987. View

Glesby M, Watson W, Brinson C, Greenberg R, Lalezari J, Skiest D . Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. J Infect Dis. 2014; 212(1):18-27. DOI: 10.1093/infdis/jiu631. View

Bahuaud M, Bodilis H, Malphettes M, Landre A, Matondo C, Bouscary D . Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study. Heliyon. 2017; 3(11):e00441. PMC: 5681344. DOI: 10.1016/j.heliyon.2017.e00441. View

Shigayeva A, Rudnick W, Green K, Chen D, Demczuk W, Gold W . Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs. Clin Infect Dis. 2015; 62(2):139-47. DOI: 10.1093/cid/civ803. View

Ohtola J, Saul-McBeth J, Iyer A, Leggat D, Khuder S, Khaskhely N . Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults. J AIDS Clin Res. 2016; 7(3). PMC: 4857877. DOI: 10.4172/2155-6113.1000556. View

Williams W, Lu P, OHalloran A, Kim D, Grohskopf L, Pilishvili T . Surveillance of Vaccination Coverage among Adult Populations - United States, 2015. MMWR Surveill Summ. 2017; 66(11):1-28. PMC: 5829683. DOI: 10.15585/mmwr.ss6611a1. View

Varughese T, Taur Y, Cohen N, Palomba M, Seo S, Hohl T . Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer. Clin Infect Dis. 2018; 67(5):687-692. PMC: 6093991. DOI: 10.1093/cid/ciy175. View

10.

Shah G, Shune L, Purtill D, Devlin S, Lauer E, Lubin M . Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. Biol Blood Marrow Transplant. 2015; 21(12):2160-2166. PMC: 4672874. DOI: 10.1016/j.bbmt.2015.08.010. View

11.

Pollard A, Perrett K, Beverley P . Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009; 9(3):213-20. DOI: 10.1038/nri2494. View

12.

Kapetanovic M, Nagel J, Nordstrom I, Saxne T, Geborek P, Rudin A . Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017; 35(6):903-908. DOI: 10.1016/j.vaccine.2016.12.068. View

13.

Rose M, Hey C, Kujumdshiev S, Gall V, Schubert R, Zielen S . Immunogenicity of pneumococcal vaccination of patients with cochlear implants. J Infect Dis. 2004; 190(3):551-7. DOI: 10.1086/422395. View

14.

van Hoek A, Andrews N, Waight P, Stowe J, Gates P, George R . The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012; 65(1):17-24. DOI: 10.1016/j.jinf.2012.02.017. View

15.

Johnson S, Rubin L, Romero-Steiner S, Dykes J, Pais L, Rizvi A . Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J Infect Dis. 1999; 180(1):133-40. DOI: 10.1086/314845. View

16.

Nived P, Jorgensen C, Settergren B . Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals. Vaccine. 2015; 33(14):1688-94. DOI: 10.1016/j.vaccine.2015.02.026. View

17.

Baxter R, Yee A, Aukes L, Snow V, Fireman B, Atkinson B . Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016; 34(36):4293-7. DOI: 10.1016/j.vaccine.2016.07.003. View

18.

Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V . Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study. Clin Infect Dis. 2015; 61(3):313-23. PMC: 4503811. DOI: 10.1093/cid/civ287. View

19.

Papadatou I, Piperi C, Alexandraki K, Kattamis A, Theodoridou M, Spoulou V . Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2014; 59(6):862-5. DOI: 10.1093/cid/ciu409. View

20.

Bogaert D, de Groot R, Hermans P . Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004; 4(3):144-54. DOI: 10.1016/S1473-3099(04)00938-7. View